Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ELTX Stock Alerts

Elicio Therapeutics (ELTX) Competitors

Elicio Therapeutics logo
$10.59 -0.18 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$10.72 +0.13 (+1.22%)
As of 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ELTX vs. CSTL, ABSI, MGTX, IVA, and GYRE

Should you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Castle Biosciences (CSTL), Absci (ABSI), MeiraGTx (MGTX), Inventiva (IVA), and Gyre Therapeutics (GYRE). These companies are all part of the "med - biomed/gene" industry.

How does Elicio Therapeutics compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Elicio Therapeutics has a net margin of 0.00% compared to Castle Biosciences' net margin of -7.02%. Castle Biosciences' return on equity of -0.89% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-7.02% -0.89% -0.74%
Elicio Therapeutics N/A -977.66%-141.55%

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Castle Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Castle Biosciences presently has a consensus price target of $46.14, indicating a potential upside of 87.57%. Elicio Therapeutics has a consensus price target of $18.00, indicating a potential upside of 69.97%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Castle Biosciences has higher revenue and earnings than Elicio Therapeutics. Castle Biosciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$344.23M2.17-$24.16M-$0.85N/A
Elicio TherapeuticsN/AN/A-$39.57M-$2.62N/A

In the previous week, Castle Biosciences had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 6 mentions for Castle Biosciences and 3 mentions for Elicio Therapeutics. Castle Biosciences' average media sentiment score of 0.74 beat Elicio Therapeutics' score of -0.20 indicating that Castle Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Castle Biosciences beats Elicio Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Elicio Therapeutics compare to Absci?

Elicio Therapeutics (NASDAQ:ELTX) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Elicio Therapeutics has a net margin of 0.00% compared to Absci's net margin of -4,113.68%. Absci's return on equity of -62.33% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -977.66% -141.55%
Absci -4,113.68%-62.33%-53.24%

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Elicio Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500.

Elicio Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 69.97%. Absci has a consensus price target of $6.44, suggesting a potential upside of 14.80%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Elicio Therapeutics is more favorable than Absci.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Absci
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Elicio Therapeutics has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.62N/A
Absci$2.80M311.46-$115.18M-$0.85N/A

In the previous week, Absci had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Absci and 3 mentions for Elicio Therapeutics. Absci's average media sentiment score of 0.46 beat Elicio Therapeutics' score of -0.20 indicating that Absci is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Absci
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Absci beats Elicio Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to MeiraGTx?

Elicio Therapeutics (NASDAQ:ELTX) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Elicio Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Elicio Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.00 beat Elicio Therapeutics' score of -0.20 indicating that MeiraGTx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MeiraGTx
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Comparatively, 7.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Elicio Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -140.31%. Elicio Therapeutics' return on equity of -977.66% beat MeiraGTx's return on equity.

Company Net Margins Return on Equity Return on Assets
Elicio TherapeuticsN/A -977.66% -141.55%
MeiraGTx -140.31%-1,065.47%-53.33%

Elicio Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Elicio Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elicio TherapeuticsN/AN/A-$39.57M-$2.62N/A
MeiraGTx$81.39M11.09-$114.20M-$1.42N/A

Elicio Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 69.97%. MeiraGTx has a consensus price target of $25.67, suggesting a potential upside of 163.25%. Given MeiraGTx's higher possible upside, analysts clearly believe MeiraGTx is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
MeiraGTx
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

MeiraGTx beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Elicio Therapeutics had 1 more articles in the media than Inventiva. MarketBeat recorded 3 mentions for Elicio Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.69 beat Elicio Therapeutics' score of -0.20 indicating that Inventiva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
Elicio Therapeutics N/A -977.66%-141.55%

Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Elicio Therapeutics has lower revenue, but higher earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$5.07M156.03-$400.67MN/AN/A
Elicio TherapeuticsN/AN/A-$39.57M-$2.62N/A

Inventiva presently has a consensus price target of $16.56, suggesting a potential upside of 205.45%. Elicio Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 69.97%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Inventiva beats Elicio Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Gyre Therapeutics has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$116.59M6.47$5.03M$0.01778.00
Elicio TherapeuticsN/AN/A-$39.57M-$2.62N/A

Gyre Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Elicio Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 3 mentions for Elicio Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 beat Elicio Therapeutics' score of -0.20 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elicio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gyre Therapeutics has a net margin of 4.31% compared to Elicio Therapeutics' net margin of 0.00%. Gyre Therapeutics' return on equity of 10.85% beat Elicio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics4.31% 10.85% 9.16%
Elicio Therapeutics N/A -977.66%-141.55%

Gyre Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 118.51%. Elicio Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 69.97%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Elicio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Elicio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Gyre Therapeutics beats Elicio Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELTX vs. The Competition

Export
MetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$201.45M$3.40B$6.25B$11.77B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-4.0422.6224.9123.23
Price / SalesN/A280.78504.5675.49
Price / CashN/A125.0643.3053.90
Price / Book117.677.059.676.69
Net Income-$39.57M$23.62M$3.55B$332.64M
7 Day Performance-1.94%3.67%1.70%2.01%
1 Month Performance-0.56%7.17%5.62%9.19%
1 Year Performance92.55%67.04%34.42%39.59%

Elicio Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELTX
Elicio Therapeutics
1.7444 of 5 stars		$10.59
-1.7%		$18.00
+70.0%		N/A$201.45MN/AN/AN/A
CSTL
Castle Biosciences
3.4593 of 5 stars		$24.49
+1.0%		$46.14
+88.4%		N/A$734.37M$344.23MN/A540
ABSI
Absci
2.5571 of 5 stars		$4.97
+5.5%		$6.44
+29.6%		N/A$732.16M$2.80MN/A210
MGTX
MeiraGTx
2.8383 of 5 stars		$9.22
+3.0%		$25.67
+178.4%		N/A$728.94M$81.39MN/A300
IVA
Inventiva
3.0392 of 5 stars		$5.13
+3.8%		$16.56
+222.7%		N/A$721M$5.07MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel